Urology Testing
Results urologists can trust
Our team of urologic pathologists provides academic-caliber, definitive diagnoses. Our pathologists utilize advanced, in-house testing, including comprehensive Immunohistochemistry (IHC) panels, to supplement morphological evaluations of difficult cases. We also offer send-out testing options including Prolaris®, Decipher, and Confirm MDX for clinicians who request it. Inform Diagnostics believes in responsible test utilization and only orders tests that are medically appropriate for accurate diagnosis.
Urology Test Offerings
Definitive diagnoses using advanced urologic testing
Our offerings for urology testing give clinicians timely, definitive answers. Our uropathologists are always available to answer clinicians’ questions so they can recommend treatment with confidence.
| Service Offering | Test Details | Category | Indications |
|---|---|---|---|
| PINgenius™ | An Inform Diagnostics-developed assay combining biomarker and histological interpretation factors | Prostate | To help predict risk of prostate cancer at rebiopsy for HGPIN patients |
| PTEN & ERG IHC | Biomarkers that detect PTEN deletion and ERG gene fusions | Prostate | To improve prostate cancer risk stratification |
| Prostate biopsy evaluation | Prostate biopsy evaluation, prostate cancer nomograms (Partin and Han tables) | Prostate | Prostate cancer detection |
| PIN4-ERG | Multiplex ERG, basal cell markers, and AMACR IHC | Prostate | To improve prostate cancer detection and resolve atypical diagnosis in prostate biopsies |
| Prolaris® | Gene expression assay | Prostate | To personalize risk stratification |
| Genomic Prostate Score® (GPS) | Molecular genomic assay | Prostate, Bladder | To personalize risk stratification |
| Decipher® | Gene expression assay | Prostate | To personalize risk stratification |
| ConfirmMDX™ for Prostate Cancer | Epigenetic assay | Prostate | To address false-negative biopsy concerns |
| Bladder and urinary tract biopsy evaluation | Bladder and urinary tract biopsy evaluation and staging | Bladder, Urinary Tract | Bladder and urinary tract cancer detection |
| Urine cytology – bladder and renal pelvic wash | Cytomophologic analysis of urothelial cells | Bladder, Urinary Tract | Bladder and urinary tract cancer detection |
| UroVysion® test | FISH measurement of chromosome 3,7,17 and loss of 9p in urothelial cells secreted in urine | Bladder | To improve bladder cancer detection complementing urine cytology |
| Renal mass biopsy evaluation | Classification of renal tumor in biopsy with application of select tumor markers panel | Kidney | To aid in treatment decision for renal mass management |
| Testis biopsy | Histological analysis of testis biopsy | Testis | Infertility evaluation |
| Testis tumor evaluation | Complete evaluation of tumor with utilization of germ cell markers IHC when applicable | Testis | Evaluation of a mass lesion |
| Skin biopsy and resections | Evaluation of skin lesions affecting penis/scrotum and perineal area | Penis, scrotum | Evaluation of a skin lesion or mass |
| HPV genotype | In situ hybridization studies of low and high-risk HPV | Penis, scrotum | To determine HPV risk potential |
